{"entity":{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","aka":["Nuvation Bio Inc."],"tldr":"Nuvation Bio is a United States-based biotechnology company running 6 late-stage cancer trials of Taletrectinib, AB-106 and NUV-1511 in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and prostate cancer.","summary":"Nuvation Bio, based in New York, NY, the United States, is a biotechnology company. A global oncology company developing therapies for difficult-to-treat cancers; its taletrectinib (IBTROZI) is FDA-approved for ROS1-positive non-small cell lung cancer. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing Taletrectinib, AB-106, NUV-1511 and safusidenib in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer, prostate cancer, pancreatic ductal adenocarcinoma and ovarian cancer. The largest, NCT06334432 (Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumours), plans to enrol 466 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.nuvationbio.com"},{"label":"ClinicalTrials.gov: trials led by Nuvation Bio","url":"https://clinicaltrials.gov/search?lead=Nuvation%20Bio%20Inc."},{"label":"Pipeline page","url":"https://www.nuvationbio.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","breast-hr-positive","prostate","pancreatic","ovarian","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["safusidenib","nuv-1511","taletrectinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07154706","nct06564324","nct04919811","nct04395677"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://www.nuvationbio.com","founded":2018,"stage":"public","investors":[],"funding":[]},"route":"/companies/nuvation-bio/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/"}],"drug":[{"id":"nuv-1511","kind":"drug","name":"NUV-1511","route":"/drugs/nuv-1511/"},{"id":"safusidenib","kind":"drug","name":"Safusidenib","route":"/drugs/safusidenib/"},{"id":"taletrectinib","kind":"drug","name":"Taletrectinib","route":"/drugs/taletrectinib/"}],"trial":[{"id":"nct06564324","kind":"trial","name":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","route":"/trials/nct06564324/"},{"id":"nct04395677","kind":"trial","name":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","route":"/trials/nct04395677/"},{"id":"nct07154706","kind":"trial","name":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","route":"/trials/nct07154706/"},{"id":"nct06334432","kind":"trial","name":"Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors","route":"/trials/nct06334432/"},{"id":"nct05303519","kind":"trial","name":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","route":"/trials/nct05303519/"},{"id":"nct04919811","kind":"trial","name":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","route":"/trials/nct04919811/"}]}}